Navigation Links
AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
Date:2/28/2008

mpowering them to grow, differentiate, and efficiently run their practices and businesses in 2008 and beyond."

Dr. Kahane added, "AMICAS has entered 2008 energized, focused, and ready to work relentlessly to reach our goals and objectives and to become the leading independent vendor of choice in the image and information management marketplace."

Looking Forward

AMICAS expects 2008 revenues to be between $52 million and $54 million, with pro-forma EBITDA expected to be between $1.0 million and $1.5 million, which is consistent with a net loss of approximately ($0.02) per share. EBITDA, a non-GAAP financial measure, refers to Net Income, adjusted for Amortization, Depreciation, Interest, and Stock Compensation expense.

A reconciliation of Net Income determined under GAAP to EBITDA is included below. Management believes that its EBITDA measurement, when viewed in addition to the Company's reported GAAP results, provides an additional meaningful measure of operating performance, enabling investors to more thoroughly evaluate current performance in comparison to past performance. This information will necessarily differ from comparable information that may be provided by other companies and should not be considered in isolation or as an alternative to the Company's operating and other financial information determined under GAAP.

Combining a market where imaging businesses continue to embrace automation as part of the response to the DRA with the combination of new product introductions already in progress, AMICAS expects 2008 bookings growth of between 10 to 20 percent. Bookings are defined as contractual commitments from customers for licenses, services, hardware, and maintenance/support.

Conference Call

AMICAS will host a conference call on Friday, February 29, at 8:30 a.m. Eastern Time to discuss the Company's 2007 fourth fiscal quarter and year end results. Investors and other interested parties may dial in to the call
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AMICAS Schedules Fourth Quarter and 2007 Year End Earnings Results Conference Call
2. AMICAS to Present at UBS Global Healthcare Services Conference
3. MedQuest Standardizes on AMICAS Vision Series PACS
4. AMICAS Solutions Closing the Loop in Radiology Communications
5. AMICAS Transforms Critical Results Notification with RadStream
6. AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow
7. Webcast Alert: AMICAS, Inc. Announces 3rd Quarter 2007 Earnings Conference Call
8. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
9. AMICAS Schedules Third Quarter Earnings Call
10. AMICAS to Present at William Blair & Company Small Cap Growth Stock Conference
11. AMICAS Hosts Complimentary DRA Education Session Featuring Timothy Trysla
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Want to Stop Cancer 3F You Can Experts Say 47763 1Want to Stop Cancer 3F You Can Experts Say 47763 2Want to Stop Cancer 3F You Can Experts Say 47763 3New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 1New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 1Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 3Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 4